Agilent and Yuntai group are committed to developing molecular diagnosis and treatment products for blood diseases and cancer

The bio industry is one of the seven strategic emerging industries determined by the Chinese government, and the bio pharmaceutical industry ranks first in the bio industry According to the prediction of the global biotechnology industry organization (bio), by 2015, China's biomedical market will reach 100 billion US dollars, and by 2020, China will become the world's largest biomedical market This year, the 12th Five Year Plan for the development of biological industry issued by the State Council pointed out that during the 12th Five Year Plan period, China will support the domestic biomedical industry in terms of policies and funds, and in the future, the R & D and innovation of new biomedical drugs in China will be strengthened Mr Lars holmkvist, senior vice president of Agilent global, President of life science and diagnostics division, and Mr Yu Han, President of Yuntai Group signed a cooperation agreement In order to promote the development of domestic biopharmaceutical field, Agilent actively sought cooperation with domestic first-class enterprises, built a perfect cooperation ecosystem, and provided customers with innovative, efficient and reliable solutions Yuntai group has a first-class international large-scale R & D and exchange platform, rich experience in research and development of pharmaceutical reagents, and has obtained a number of products with independent intellectual property rights in the field of molecular diagnosis and treatment of many tumors, such as leukemia, lymphoma, lung cancer and colon cancer, and is the leader in this field Based on the complementary advantages, the two sides will establish a long-term, mutually beneficial partnership, which is in line with the current good development trend in the field of biopharmaceutical at home and abroad, and will create achievements for the international and domestic medical circles Both sides will devote themselves to the research and development of new technologies and products, and achieve "win-win" in various aspects such as the standardization of molecular diagnosis and treatment industry standards for blood diseases and cancer diseases, and the development of molecular diagnosis market at home and abroad, so as to ultimately benefit human health As a technology leader in the field of life science and diagnosis, Agilent has always strived to build a product line of life science and diagnosis, and established a system biology solution integrating genomics, proteomics and metabolism Its products cover a wide range of fields such as biology, medicine, pharmacy, food and environmental monitoring, providing first-class products and technical solutions for basic research and application research 。 At the same time, with the launch of Agilent's spin off strategy, new Agilent will focus on life science, diagnosis and application testing (LDA), and will strive to become a global leader in this field after the spin off Mr Lars holmkvist, senior vice president of Agilent global and President of life science and diagnosis division, delivered a keynote speech, Lars said: "health is the top priority for all mankind, and it is also the work focus that the Chinese government has been focusing on While maintaining our business growth and strengthening our leading position in the field of technology, it is also our important responsibility to join hands with domestic excellent enterprises to build a perfect partner ecosystem and let our technology and products benefit the Chinese people The cooperation with Yuntai group is one of the important measures for us to practice the strategy of "taking root in China" "We are very happy to work with Agilent, the global leader," said Ms Xiong Our cooperation with Agilent will help us make full use of our technological advantages, overcome human diseases and create new commercial benefits by providing advanced biopharmaceutical technologies and products "After the signing ceremony, Mr Lars holmkvist, senior vice president of Agilent's life science and diagnosis business division, and Ms Xiong Hui, general manager of Yuntai group, etc were interviewed by the media When the media asked why Mr Lars holmkvist chose Yuntai group among many excellent biomedical companies in China, they said: Agilent attaches great importance to the choice of partners It points out that the criteria for Agilent to choose partners are: a company with good employees, the company's management with Western learning or management experience, and emphasizes that the most important thing for Agilent is to have the ability of continuous innovation, and Yuntai is such a company When asked what kind of cooperation Ms Xiong Hui will carry out with Agilent and whether all product lines will start to cooperate with Agilent, the reporter said: Agilent's product line is very long and its technology is leading, which will help the long-term development of Yuntai group At present, we are considering gradual development, mutual benefit and win-win cooperation step by step We hope that we can walk faster on the shoulders of giants The development of biomedical industry will help China achieve breakthrough and innovation in various disease treatment fields, and make up for a large number of unmet medical needs, especially in the fields of blood diseases, cancer, infectious diseases and disease gene detection services Agilent works closely with Yuntai group to develop molecular diagnosis and treatment products for blood diseases The two sides hope to take this cooperation as an opportunity to promote comprehensive cooperation in clinical metabonomics, clinical proteomics, clinical genomics and other fields, so as to play a social responsibility of enterprises for the international development of China's biomedical industry and the health of the Chinese people (BIOON Com) Agilent Technologies (NYSE: a) is the world's leading test and measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications The company has 20600 employees in more than 100 countries around the world, providing excellent services to customers In fy2013, Agilent's net income reached $6.8 billion For more information about Agilent, please visit Yuntai group is a group company dedicated to the R & D, production and service of biomedical science and technology Its subsidiaries include Shanghai Yuanqi Biomedical Technology Co., Ltd., Suzhou Yuntai Biomedical Technology Co., Ltd and Shanghai austai medical laboratory Co., Ltd Shanghai Yuanqi Biomedical Technology Co., Ltd., established in January 2010, is a company dedicated to the R & D and production of individual molecular diagnostic reagent products At present, the enterprise has a clean workshop of nearly 1000 square meters that meets the requirements of the in vitro diagnostic reagent production system of the State Food and Drug Administration (CFDA), has passed the CFDA certification, and has four molecular diagnostic products completed the R & D offline, and has passed the CFDA audit to obtain the product registration certificate Suzhou Yuntai Biomedical Technology Co., Ltd was established in January 2013 Ms Xiong Hui, President of the company, is the founder of the company The company is the sole agent of four registered products of Shanghai Yuanqi Biomedical Technology Co., Ltd in China at present The company operates according to the modern scientific and technological project management mechanism and operation mode, according to the modern enterprise system, combined with the existing company team, relying on the existing molecular genetic diagnosis product development technology platform, medical testing technology platform and gene detection technology Platform, forming the technology combination of the whole industrial chain At present, the company has obtained three types of in vitro diagnostic kit medical device sales license, and the production license will be approved in the near future Relying on the R & D, production and sales of Yuntai group, Shanghai austai medical laboratory Co., Ltd integrates the individualized diagnosis and treatment of tumor and establishes the detection platform of morphology, immunity, genetics and molecular biology, involving the specialized detection fields of Pathology, hematology, individualized solid tumor and molecular genetics The quality management system established by the company is in strict accordance with the national ISO15189 standard and the cap approval requirements of the United States.